Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Memorial Sloan Kettering Cancer Center
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age18 - 79 years old
Diagnosed with any type of lymphoma \[Hodgkin, non-Hodgkin (B- or T-cell)\] and planned for BEAM-AHCT
KPS \> 70
Cardiac ejection fraction of \> 45%
Hemoglobin-adjusted diffusing capacity of carbon monoxide (DLCO) of ≥45%
Creatinine clearance of ≥ 40 mL/min
Completion of most recent systemic therapy within 12 weeks of enrollment
Complete or partial response to systemic chemotherapy by IWG Working Group Criteria.
Total bilirubin \< 2.0 mg/dL in the absence of suspected Gilbert's disease (if Gilbert's disease is suspected, the total bilirubin must be ≤3.0 mg/dL), and AST \& ALT \< 2.5 ULN.
Minimum stem cell dose of 2 x 10\*6 CD34+ cells/kg
You may not be if
Disease progression by IWG Working Group since last therapy
Pregnant or lactating females
Contraindication to CE melphalan or any of the required supportive treatments, including hypersensitivity to G-CSF or pegfilgrastim
Any known allergy or allergic reactions to Captisol
Any other medical condition or laboratory evaluation that, in the treating physician's or principal investigator's opinion, makes the patient unsuitable to participate in this clinical trial
Clareo Health | A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
